Patents by Inventor Philippe Mondon

Philippe Mondon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210052480
    Abstract: At least one cyclic peptide is described for use as an active component in a non-therapeutic cosmetic treatment of the skin and/or its appendages, the cyclic peptide consisting of at least five amino acids including at least one proline (Pro) and at least one two phenylalanine (Phe), the other amino acids being chosen from the group comprising leucine (Leu), isoleucine (Ile), valine (Val), alanine (Ala), glycine (Gly), methionine (Met) and tryptophan (Trp), methionine (Met), when present, may be unoxidized or oxidized.
    Type: Application
    Filed: January 29, 2019
    Publication date: February 25, 2021
    Inventors: Philippe Mondon, Emmanuel Doridot, Thibault Marchand
  • Patent number: 10758473
    Abstract: According to the present invention, an extract is obtained from the Globularia genus is obtained from a plant of the genus Globularia and is used for a non-therapeutic cosmetic treatment of the skin and/or appendages. Preferably the species is Globularia cordifolia and the extract is obtained by in vitro plant culture. The extract can be used for preventing and/or treating skin ageing by stimulating the reactions of detoxification and cellular regeneration through a hormetic type response, for improving the transparency and radiance of complexion, for preventing or treating sensitive and reactive skins, for preventing or treating rednesses, for preventing protein glycation, for increasing and/or maintaining the number of dermal stem cells, for increasing and/or maintaining the dermal macromolecules, in particular collagen and elastin, for increasing the volume of the dermis, for preventing and/or treating fines lines and wrinkles, for firming skin, for preventing hair loss and/or stimulating hair regrowth.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: September 1, 2020
    Assignee: Sederma, S.A.S.
    Inventors: Arnaud Fournial, Claire-Marie Grizaud, Philippe Mondon, Caroline Le Moigne
  • Publication number: 20200253852
    Abstract: The invention is directed to the use of at least one peptide of formula: X-(Xaa1)n-Pro*-(Xaa2)m-Y (I) With: -n=0, 1 or 2; -m=0 or 1 and if m=0 then n?0 -Xaa1 is: -An hydrophobic aminoacid selected from Alanine (Ala, A), Valine (Val, V), Methionine (Met, M), Leucine (Leu, L), Isoleucine (Ile, I), Phenylalanine (Phe, F), Proline (Pro, P) and analogues and derivatives thereof; -A polar aminoacid selected from Serine (Ser, S), Threonine (Thr, T), Tyrosine (Tyr, Y), Asparagine (Asn, N), Glutamine (Gln, Q) and analogues and derivatives thereof; -or Glycine (Gly, G); When n=2 the two aminoacids Xaa1 can be the same or different; -Xaa2 is: -An hydrophobic aminoacid selected from Alanine (Ala, A), Valine (Val, V), Methionine (Met, M), Leucine (Leu, L), Isoleucine (Ile, I), Phenylalanine (Phe, F), Proline (Pro, P) and analogues and derivatives thereof; -A basic aminoacid selected from Arginine (Arg, R), Lysine (Lys, K) and Histidine (His, H) and analogues and derivatives thereof; -Glycine (Gly, G) or Serine (Ser, S); -
    Type: Application
    Filed: April 14, 2020
    Publication date: August 13, 2020
    Applicant: Sederma
    Inventors: Olivier Peschard, Philippe Mondon
  • Patent number: 10722452
    Abstract: The invention proposes to use a plant material derived from Marrubium vulgare for a non-therapeutic cosmetic treatment for tightening skin pores, said plant material comprising an effective amount of Forsythoside B as the active molecule. The plant material is preferably constituted of a cellular extract of dedifferentiated plant cells freed from cellular debris. This treatment is particularly intended for refining skin grain and/or for treating skin with an oily tendency.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: July 28, 2020
    Assignee: Sederma
    Inventors: Caroline Ringenbach, Emmanuel Doridot, Philippe Mondon
  • Patent number: 10668000
    Abstract: The peptides have the general following formula: X-Pro*-Pro*-Xaa-Y in which: •Xaa is selected from Leucine (Leu, L), Arginine (Arg, R), Lysine (Lys, K), Alanine (Ala, A), Serine (Ser, S), and Aspartic acid (Asp, D); •At the N terminal end of the peptide, X is selected from H, —CO—R1 and —SO2—R1; •At the C terminal end of the peptide, Y is selected from OH, OR1, NH2, NHR1 and NR1R2; •R1 and R2 are, independently from each other, selected from an alkyle, aryle, aralkyle, alkylaryl, alkoxy and aryloxy group, that can be linear, branched, cyclic, poly-cyclic, non-saturated, hydroxylated, carbonylated, phosphorylated and/or sulfured, and which skeletum can comprise an heteroatom, in particular an O, S and/or N atom; •Pro* correspond to a Proline, an analogue or derivative thereof; •if X is H then Y is selected from OR1, NH2, NHR1 and NR1R2, and if Y is OH then X is —CO— or —SO2—R1; and the peptide hypoxanthine-Pro-Pro-Arg being excluded.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: June 2, 2020
    Assignee: SEDERMA
    Inventors: Olivier Peschard, Anne Doucet, Richard Leroux, Philippe Mondon
  • Patent number: 10660839
    Abstract: The invention is directed to the use of at least one peptide of formula: X-(Xaa1)n-Pro*-(Xaa2)m-Y (I) With: —n=0, 1 or 2; —m=0 or 1 and if m=0 then n?0 —Xaa1 is: —An hydrophobic aminoacid selected from Alanine (Ala, A), Valine (Val, V), Methionine (Met, M), Leucine (Leu, L), Isoleucine (Ile, I), Phenylalanine (Phe, F), Proline (Pro, P) and analogues and derivatives thereof; —A polar aminoacid selected from Serine (Ser, S), Threonine (Thr, T), Tyrosine (Tyr, Y), Asparagine (Asn, N), Glutamine (Gln, Q) and analogues and derivatives thereof; —or Glycine (Gly, G); When n=2 the two aminoacids Xaa1 can be the same or different; —Xaa2 is: —An hydrophobic aminoacid selected from Alanine (Ala, A), Valine (Val, V), Methionine (Met, M), Leucine (Leu, L), Isoleucine (Ile, I), Phenylalanine (Phe, F), Proline (Pro, P) and analogues and derivatives thereof; —A basic aminoacid selected from Arginine (Arg, R), Lysine (Lys, K) and Histidine (His, H) and analogues and derivatives thereof; —Glycine (Gly, G) or Serine (Ser, S); —
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: May 26, 2020
    Assignee: Sederma
    Inventors: Olivier Peschard, Philippe Mondon
  • Publication number: 20190269595
    Abstract: The invention provides a method for the topical non therapeutical cosmetic treatment of the scalp comprising applying to the scalp an effective amount of at least one alkyl-phthalide or a plant extract comprising mainly said alkyl-phthalide. In particular, the treatment is an anti-dandruff treatment. According to the invention, a CO2 supercritical extract of Apium graveolens seeds consisting mainly of sedanenolide may be used.
    Type: Application
    Filed: May 16, 2019
    Publication date: September 5, 2019
    Applicant: Sederma
    Inventors: Olga Gracioso, Caroline Ringenbach, Thibault Marchand, Philippe Mondon, Nicolas Barriere
  • Patent number: 10335354
    Abstract: The invention provides the use of at least one alkyl-phthalide or a plant extract comprising mainly said alkyl-phthalide for the topical cosmetic treatment of the skin and of the scalp, in particular an anti-dandruff treatment. According to the invention, a CO2 supercritical extract of Apium graveolens seeds consisting mainly of sedanenolide may be used.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: July 2, 2019
    Assignee: SEDERMA
    Inventors: Olga Gracioso, Caroline Ringenbach, Thibault Marchand, Philippe Mondon, Nicolas Barriere
  • Publication number: 20190153030
    Abstract: The peptide has from 3 to 10 amino acids comprising at least the sequence K*(Ac)GH or K*(Ac)HG and may further comprise an N-terminus modification, preferably an acylation, and/or a C-terminus modification; K* is selected from the group consisting of lysine, ornithine, diaminobutyric acid, diaminopropionic acid and a hydroxylated derivative thereof; K*(Ac) corresponds to a lysine, ornithine, diaminobutyric acid, diaminopropionic acid or a hydroxylated derivative thereof, acetylated on the amine of their lateral hydrocarbon chain. The two preferred peptides are Pal-K(Ac)GH and Pal-K(Ac)HG. This peptide can be used for a cosmetic treatment, in particular anti-aging, anti-wrinkle and fine lines, to improve the mechanical properties of the skin, firmness/tonicity/elasticity/flexibility, to increase the density and volume of the skin, for a restructuring, healing effect, and/or to fight stretch marks.
    Type: Application
    Filed: June 13, 2017
    Publication date: May 23, 2019
    Applicant: Sederma
    Inventors: Olivier Peschard, Anne Doucet, Richard Leroux, Philippe Mondon
  • Publication number: 20190142723
    Abstract: The invention is directed to the use of at least one peptide of formula: X-(Xaa1)n-Pro*-(Xaa2)m-Y (I) With: —n=0, 1 or 2; —m=0 or 1 and if m=0 then n?0 —Xaa1 is: —An hydrophobic aminoacid selected from Alanine (Ala, A), Valine (Val, V), Methionine (Met, M), Leucine (Leu, L), Isoleucine (Ile, I), Phenylalanine (Phe, F), Proline (Pro, P) and analogues and derivatives thereof; —A polar aminoacid selected from Serine (Ser, S), Threonine (Thr, T), Tyrosine (Tyr, Y), Asparagine (Asn, N), Glutamine (Gln, Q) and analogues and derivatives thereof; —or Glycine (Gly, G); When n=2 the two aminoacids Xaa1 can be the same or different; —Xaa2 is: —An hydrophobic aminoacid selected from Alanine (Ala, A), Valine (Val, V), Methionine (Met, M), Leucine (Leu, L), Isoleucine (Ile, I), Phenylalanine (Phe, F), Proline (Pro, P) and analogues and derivatives thereof; —A basic aminoacid selected from Arginine (Arg, R), Lysine (Lys, K) and Histidine (His, H) and analogues and derivatives thereof; —Glycine (Gly, G) or Serine (Ser, S); —
    Type: Application
    Filed: January 28, 2019
    Publication date: May 16, 2019
    Applicant: Sederma
    Inventors: Olivier Peschard, Philippe Mondon
  • Publication number: 20190099362
    Abstract: The invention proposes to use a plant material derived from Marrubium vulgare for a non-therapeutic cosmetic treatment for tightening skin pores, said plant material comprising an effective amount of Forsythoside B as the active molecule. The plant material is preferably constituted of a cellular extract of dedifferentiated plant cells freed from cellular debris. This treatment is particularly intended for refining skin grain and/or for treating skin with an oily tendency.
    Type: Application
    Filed: March 21, 2017
    Publication date: April 4, 2019
    Applicant: Sederma
    Inventors: Caroline Ringenbach, Emmanuel Doridot, Philippe Mondon
  • Patent number: 10231917
    Abstract: The invention is directed to the use of at least one peptide of formula: X—(Xaa1)n-Pro*-(Xaa2)m-Y (I) With: —n=0, 1 or 2; —m=0 or 1 and if m=0 then n?0-Xaai is: —An hydrophobic amino acid; —A polar amino acid; —or Glycine (Gly, G); When n=2 the two amino acids Xaa1 can be the same or different; —Xaa2 is: —An hydrophobic amino acid; —A basic amino acid Glycine (Gly, G) or Serine (Ser, S); —At the N terminal end of the peptide, X is selected from H, —CO—R1 and —SO2—R1; —At the C terminal end of the peptide, Y is selected from OH, OR1, NH2, NHR1 or NR1R2, R1 and R2 being independently from each other, selected from an alkyle, aryle, aralkyle, alkylaryl, alkoxy and aryloxy group; Excluding the peptides where X=H and Y=OH, for a non therapeutical cosmetic pro-pigmenting treatment of skin.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: March 19, 2019
    Assignee: Sederma
    Inventors: Olivier Peschard, Philippe Mondon
  • Patent number: 10159636
    Abstract: The present invention relates to the field of cosmetic and dermopharmaceutical compositions. It concerns oligomer compounds of D-glucuronic acid or D-glucuronate with a ? (1-4) sequence (or oligoglucuronans) containing a degree of acetylation specifically between 8.7±0.5 and 9.2±0.5% by weight of O—CO—CH3 group compared to the weight of glucuronic acid and with a degree of polymerisation (DP) of 18-19±2. The oligomer compounds according to the present invention are intended to stimulate the elasticity of the dermis and epidermis although they also act to increase dermo-epidermal cohesion in order to combat skin ageing, lines, wrinkles, visible and/or tactile skin discontinuities, loss of firmness, elasticity and tone and to combat skin tissue deformability. The invention also concerns a cosmetic composition containing at least one compound as recited according to the present invention.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: December 25, 2018
    Assignee: Sederma, S.A.S.
    Inventors: Arnaud Fournial, Claire-Marie Grizaud, Caroline Le Moigne, Philippe Mondon
  • Publication number: 20180355034
    Abstract: The present invention relates to the use of antibody Fc fragments in the treatment of autoimmune and/or inflammatory diseases, said Fc fragments being isolated recombinant Fc fragments having a modified affinity for at least one of the Fc receptors (FcR), particularly an increased affinity to FcRn.
    Type: Application
    Filed: July 6, 2016
    Publication date: December 13, 2018
    Applicant: Laboratoire Français du Fractionnement et des Biotechnologies
    Inventors: Philippe Mondon, Céline Monnet-Mars, Alexandre Fontayne, Christophe De Romeuf, Abdessatar Chtourou
  • Publication number: 20180318204
    Abstract: The extract of plant origin is characterized in that it is obtained from a plant of the genus Globularia, preferably the species Globularia Cordifolia. The extract according to the invention can be obtained by in vitro plant culture of undifferentiated cells. It can be used as an active agent in a composition for preventing and/or treating skin aging by stimulating detoxification reactions and cellular regeneration thanks to a hormetic type response. With such a composition, improvement of the visual appearance of the skin, radiance and transparency of complexion is obtained for example.
    Type: Application
    Filed: March 23, 2018
    Publication date: November 8, 2018
    Applicant: Sederma
    Inventors: Arnaud Fournial, Claire-Marie Grizaud, Philippe Mondon, Caroline Le Moigne
  • Publication number: 20180169297
    Abstract: The present invention concerns an injectable composition comprising FVII and a filler, and its use for preventing or treating body and skin defects, especially folds, wrinkles, skin depressions and scars, while diminishing, decreasing or avoiding skin reactions due to injection, specially redness, ecchymosis, bruising, bleeding, erythema, oedema, necrosis, ulceration, swelling and/or inflammation.
    Type: Application
    Filed: June 10, 2016
    Publication date: June 21, 2018
    Applicant: Laboratoire Français du Fractionnement et des Biotechnologies
    Inventors: Abdessatar Chtourou, Jean-Luc Plantier, Philippe Mondon
  • Patent number: 9925135
    Abstract: According to the present invention the extract of plant origin of the Globularia genus is used for a non-therapeutic cosmetic treatment of the skin and/or appendages. Preferably the species is Globularia cordifolia and the extract is obtained by in vitro plant culture. The extract can be used in particular for preventing and/or treating skin ageing by stimulating the 10 reactions of detoxification and cellular regeneration through a hormetic type response, for improving the transparency and radiance of complexion, for preventing or treating sensitive and reactive skins, for preventing or treating rednesses, for preventing protein glycation, for increasing and/or maintaining the number of dermal stem cells, for increasing and/or maintaining the dermal macromolecules, in particular collagen and elastin, for increasing the volume of the dermis, for 15 preventing and/or treating fines lines and wrinkles, for firming skin, for preventing hair loss and/or stimulating hair regrowth.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: March 27, 2018
    Assignee: Sederma, S.A.S.
    Inventors: Arnaud Fournial, Claire-Marie Grizaud, Philippe Mondon, Caroline Le Moigne
  • Publication number: 20180030111
    Abstract: Disclosed is to a polypeptide including a mutated Fc region and having functional activity, mediated by the Fc region, that is modified compared with that of a parent polypeptide. The Fc region includes at least one combination of 2 mutations, the combination being selected from among one mutation selected from among a first set of mutations, and at least one mutation selected from among a second set of mutations, and provided that mutation (i) does not take place on the same amino acid as mutation (ii). Also disclosed are use of the polypeptide, compositions including the same, and methods for preparing the polypeptide.
    Type: Application
    Filed: May 6, 2016
    Publication date: February 1, 2018
    Inventors: Celine MONNET, Philippe MONDON, Alexandre FONTAYNE, Christophe DE ROMEUF
  • Publication number: 20180000717
    Abstract: The peptidic compound comprises at least an aminoacid which is lysine, ornithine, diaminopropionic acid or diaminobutyric acid or a derivative of these aminoacids, on which a carboxylic acid is grafted via a peptidic bound on the nitrogen of the lateral chain, said carboxylic acid comprising a (poly)cycle or (poly)heterocycle. Preferably, the grafted carboxylic acid is an aminoacid or a derivative, in particular selected from, a proline, a hydroxyproline or pyroglutamic acid. The peptidic compound can stimulate the synthesis of the main molecules constituting the extracellular matrix of the skin, especially collagen 1 and 4 and elastin. It can be used for topical cosmetic treatment such as a global anti-aging treatment, or for specific activities, including anti-wrinkles, moisturizing, to improve the mechanical properties of the skin, firmness/tone/elasticity/flexibility, to increase density and volume of the skin, improve skin radiance, for a restructuring effect and/or to fight stretch marks.
    Type: Application
    Filed: December 14, 2015
    Publication date: January 4, 2018
    Applicant: SEDERMA
    Inventors: Olivier Peschard, Anne Doucet, Richard Leroux, Philippe Mondon
  • Patent number: RE46585
    Abstract: A variant of a parent polypeptide including an Fc region, which variant exhibits increased binding to FcRn as compared to the parent polypeptide and includes at least one amino acid modification in the Fc region.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: October 24, 2017
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Christian Behrens, Sylvie Jorieux, Abdelhakim Kharrat, Khalil Bouayadi, Philippe Mondon, Celine Monnet-Mars